Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Castleman disease (CD) is a group of rare and heterogenous lymphoproliferative disorders including unicentric CD (UCD), human herpesvirus-8(HHV-8)-associated multicentric CD (HHV8-MCD), and HHV-8-negative/idiopathic multicentric CD (iMCD). Knowledge of CD mainly comes from case series or retrospective studies, but the inclusion criteria of these studies vary because the Castleman Disease Collaborative Network (CDCN) diagnostic criteria for iMCD and UCD were not available until 2017 and 2020, respectively. Further, these criteria and guidelines have not been systematically evaluated.
Methods: In this national, multicenter, retrospective study implementing CDCN criteria, we enrolled 1634 CD patients (UCD, n = 903; MCD, n = 731) from 2000 to 2021 at 40 Chinese institutions to depict clinical features, treatment options, and prognostic factors of CD.
Findings: Among UCD, there were 162 (17.9%) patients with an MCD-like inflammatory state. Among MCD, there were 12 HHV8-MCD patients and 719 HHV-8-negative MCD patients, which included 139 asymptomatic MCD (aMCD) and 580 iMCD meeting clinical criteria. Of 580 iMCD patients, 41 (7.1%) met iMCD-TAFRO criteria, the others were iMCD-NOS. iMCD-NOS were further divided into iMCD-IPL (n = 97) and iMCD-NOS without IPL (n = 442). Among iMCD patients with first-line treatment data, a trend from pulse combination chemotherapy toward continuous treatment was observed. Survival analysis revealed significant differences between subtypes and severe iMCD (HR = 3.747; 95% CI: 2.112-6.649, < 0.001) had worse outcome.
Interpretation: This study depicts a broad picture of CD, treatment options and survival information in China and validates the association between the CDCN's definition of severe iMCD and worse outcomes, requiring more intensive treatment.
Fundings: Beijing Municipal Commission of Science and Technology, CAMS Innovation Fund and National High Level Hospital Clinical Research Funding.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240357 | PMC |
| http://dx.doi.org/10.1016/j.lanwpc.2023.100720 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Hyaline vascular Castleman disease with indolent T-lymphoblastic proliferation complicated by paraneoplastic autoimmune multiorgan syndrome: report of a case].
Zhonghua Bing Li Xue Za Zhi
September 2025
Department of Pathology, Xi'an Children's Hospital, Xi'an Jiaotong University, Xi'an 710043, China.
Atypical clinical presentation associated with Castleman disease: a case report and review of the literature.
Front Med (Lausanne)
August 2025
Department of Pathology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
Background: Castleman disease (CD) is a group of rare and complicated diseases characterized by systemic inflammation, lymphadenopathy, and multiorgan involvement. It is often misdiagnosed as an infection, an autoimmune disease, or a malignant cancer.
Case Presentation: In this case, we report a 33-year-old Chinese male patient who was diagnosed with idiopathic multicentric Castleman disease (iMCD).
[18F]FDG PET/CT in pulmonary Castleman's disease.
Rev Esp Med Nucl Imagen Mol (Engl Ed)
September 2025
Department of Nuclear Medicine, Sichuan Science City Hospital, Mianyang, Sichuan, China.
Unicentric Castleman disease treated with rituximab before surgery: clinicopathologic findings.
Ann Hematol
September 2025
Department of Molecular Medicine, University of Pavia, Pavia, Italy.
Castleman disease (CD) is a rare lymphoproliferative disorder with unique clinicopathological features, including two distinct clinical subtypes categorized as unicentric (UCD) and multicentric (MCD). UCD usually involves a single lymph node site presenting with no or minimal local symptoms. Histologically, most UCD cases exhibit regressive hyaline vascular germinal centers, characterized by penetrating vessels, dendritic hyperplasia/dysplasia, and increased interfollicular vascularity.
View Article and Find Full Text PDFHIV-Associated Multicentric Castleman Disease with Kaposi Sarcoma: A Case Report with 120-Week Follow-Up of HHV-8 After Remission.
J Infect Chemother
September 2025
AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan; Center for AIDS Research, Kumamoto University, Kumamoto, Japan.
HIV-associated multicentric Castleman disease (HIV-MCD) is a rare, life-threatening lymphoproliferative disorder featuring systemic inflammation and marked lymphadenopathy. HIV-MCD is characterized by a human herpesvirus-8 (HHV-8) infection, with an increasing incidence despite advances in antiretroviral therapy (ART). Although HHV-8 viremia is a recognized indicator of disease recurrence, the necessity of intervention for low-level viremia reactivation remains unclear.
View Article and Find Full Text PDF